生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

未开盘 01-12 16:00:00 EST

1,115.12

-5.69

-0.51%

最高1,121.09	最低1,102.75	成交量8.95亿
今开1,120.81	昨收1,120.81	日振幅1.64%
总市值0.00	流通市值0.00	总股本0.00
成交额198.39亿	换手率--	流通股本0.00
市净率7.165916	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1115.1216,"timestamp":1768251599999,"preClose":1120.812,"halted":0,"volume":895499112,"delay":0,"changeRate":-0.005077,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-5.69043,"latestTime":"01-12 16:00:00 EST","open":1120.812,"high":1121.0859,"low":1102.754,"amount":19838880085.044846,"amplitude":0.016356,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768314600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.165916,"peRate":-127.264641,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2603575413","title":"基因药物开发取得进展 Beam Therapeutics (BEAM.US)股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575413","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575413?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:16","pubTimestamp":1768270560,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，Beam Therapeutics  股价在周一大幅上涨超20%，截至收盘，该股涨22.29%，报33.69美元，此前该公司发布了关于持续致力于建立可持续、可预测模式以推进精准基因药物开发的最新进展。截至 2025 年底，公司持有的现金、现金等价物及有价证券估值约为 12.5 亿美元;预计运营资金支持期限将延长至 2029 年，这将为 risto-cel 的预期上市以及 BEAM-302 关键开发计划的执行提供有力支持。此外，该公司肝脏靶向基因疾病特许经营项目的扩张正在进行中，","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BEAM","BK4007","LENZ","BK4588","BK4535","BK4505","BK4611","BK4585","BK4539","BK4556","BK4139"],"gpt_icon":0},{"id":"1148445500","title":"安进：Maritide扩展研究52周数据显示，绝大多数受试者采用较低月剂量或季度剂量后维持二期试验第一阶段减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1148445500","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148445500?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:53","pubTimestamp":1768262001,"startTime":"0","endTime":"0","summary":"安进公司最新公布的Maritide扩展研究结果显示，在为期52周的延长试验期间，绝大多数接受较低月度剂量或季度剂量给药的参与者，成功维持了在二期临床试验第一阶段所达到的体重减轻效果。这项扩展研究旨在评估不同给药方案对体重维持的长期影响，初步数据表明药物在延长用药周期后仍能保持疗效稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0109394709.USD","LU1061106388.HKD","LU1023059063.AUD","LU1983299246.USD","LU2112291526.USD","LU0889565916.HKD","BK4588","LU0058720904.USD","IE0002141913.USD","BK4139","LU0122379950.USD","LU0868494617.USD","SG9999001440.SGD","AMGN","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4534","IE00B2B36J28.USD","LU1571399168.USD","LU2242652126.USD","LU0289739699.SGD","LU2242646821.SGD","BK4585","BK4581","LU1057294990.SGD","IE00BJT1NW94.SGD","LU2468319806.SGD","IE0009355771.USD","LU2089984988.USD","BK4599","IE00BFTCPJ56.SGD","BK4533","BK4566"],"gpt_icon":0},{"id":"1117228263","title":"安进：Maritide治疗第二年耐受性良好，季度剂量方案下恶心呕吐发生率极低且无新增安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1117228263","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117228263?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:53","pubTimestamp":1768261997,"startTime":"0","endTime":"0","summary":"安进公司最新研究数据显示，其药物Maritide在第二年治疗期间展现出优异的耐受性特征。值得注意的是，即便是采用季度给药方案，患者的不良反应发生率仍维持在极低水平。\n临床观察表明，治疗组恶心和呕吐等胃肠道不良事件的发生率显著偏低。更关键的是，在整个第二年研究周期内，未监测到任何新的安全性信号，这进一步印证了该疗法的可靠性和安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1057294990.SGD","AMGN","BK4599","IE00B2B36J28.USD","BK4139","LU2468319806.SGD","LU0122379950.USD","LU1023059063.AUD","BK4581","BK4534","LU2089984988.USD","LU2112291526.USD","IE00B4R5TH58.HKD","BK4585","LU0289739699.SGD","SG9999001440.SGD","BK4533","IE0002141913.USD","LU0058720904.USD","LU1983299246.USD","LU1571399168.USD","BK4588","LU0320765992.SGD","LU0868494617.USD","LU1061106388.HKD","LU2242652126.USD","LU2242646821.SGD","LU0889565916.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2603522166","title":"查获作案工具及嫌疑人DNA 调查人员透露更多卢浮宫失窃案细节","url":"https://stock-news.laohu8.com/highlight/detail?id=2603522166","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603522166?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:52","pubTimestamp":1768261920,"startTime":"0","endTime":"0","summary":"据央视新闻消息，当地时间1月12日，根据调查人员透露的消息，警方曾发现一处隐藏的作案工具库，这一发现表明卢浮宫盗抢案是一次有组织、有准备的专业犯罪，而非临时起意。在对其实施抓捕时，调查人员搜查了他的口袋，发现了一把钥匙，对应的就是这处位于拉库尔讷夫的旧自行车存放间。斯利曼·K被怀疑是卢浮宫盗抢团伙中的第三名成员，目前仍被推定为无罪。截至目前，被盗珠宝仍未被找到。","market":"sh","thumbnail":"https://media.bjnews.com.cn/image/2026/01/13/5675049887511685462.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/image/2026/01/13/5675049887511685462.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1768261671129155.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1768261671129155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK4121","BK4139","BK4109","DNA"],"gpt_icon":0},{"id":"1139121916","title":"安进：每月注射马利肽的24周研究显示2型糖尿病患者糖化血红蛋白与体重均现强劲且具临床意义的下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1139121916","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139121916?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:50","pubTimestamp":1768261815,"startTime":"0","endTime":"0","summary":"安进公司公布的一项为期24周的研究结果显示，在2型糖尿病患者中，每月注射一次马利肽（Maritide）能够显著且具有临床意义地降低患者的糖化血红蛋白（HbA1c）水平和体重。该研究数据展现出积极的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","AMGN","LU1983299246.USD","BK4599","LU0122379950.USD","LU0289739699.SGD","LU2112291526.USD","IE0009355771.USD","LU1061106388.HKD","BK4585","LU2089984988.USD","BK4139","SG9999001440.SGD","LU2242652126.USD","LU1057294990.SGD","BK4581","IE00B4R5TH58.HKD","LU0889565916.HKD","BK4588","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4534","LU1571399168.USD","LU0109394709.USD","BK4566","LU2242646821.SGD","LU0868494617.USD","LU1023059063.AUD","IE0002141913.USD","LU2468319806.SGD","LU0058720904.USD","BK4533"],"gpt_icon":0},{"id":"1107664320","title":"艾伯维公司未来十年将斥资1000亿美元投入美国研发及资本开支，涵盖制造业","url":"https://stock-news.laohu8.com/highlight/detail?id=1107664320","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107664320?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:32","pubTimestamp":1768260770,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，将在未来十年内于美国市场投入高达1000亿美元的资金，重点投向研发活动以及资本性支出，其中制造业相关投资亦被纳入这一庞大计划。这一战略部署彰显了公司对强化本土创新能力和生产基础设施的长期承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU1551013342.USD","IE00B42XCP33.USD","LU1244550221.USD","LU0158827948.USD","LU1023059063.AUD","LU0114720955.EUR","LU2089283258.USD","LU0738911758.USD","LU1718418525.SGD","LU2129689605.HKD","LU2237443895.HKD","BK4588","IE00BGHQF631.EUR","LU0553294199.USD","LU0234572021.USD","IE00BFTCPJ56.SGD","LU0689626769.HKD","IE00B4R5TH58.HKD","SG9999015952.SGD","LU0122379950.USD","LU0320765646.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1983299246.USD","BK4139","BK4550","SG9999015986.USD","LU1267930573.SGD","LU0689472784.USD","IE00BSNM7G36.USD","IE0004445239.USD","LU0289739699.SGD","LU0965509010.AUD","LU0861579265.USD","LU1732799900.SGD","LU2089984988.USD","SG9999003800.SGD","IE00B3PB1722.GBP","LU1989772923.USD","IE00B2B36J28.USD","BK4585","LU2129689431.USD","LU2237443549.SGD","LU2129689514.USD","LU0256863811.USD","LU1989771016.USD","LU2237443382.USD","LU2089284900.SGD","LU0965508806.USD","LU0029864427.USD","IE0002141913.USD","LU2112291526.USD","LU1093756325.SGD","IE00BJT1NW94.SGD","SG9999015978.USD","LU1244550494.USD","LU1934455194.USD","LU0256863902.USD","LU2237443622.USD","LU0203345920.USD","LU1934455863.HKD","LU0310799852.SGD","LU1074936037.SGD","IE0009355771.USD","IE00BVYPNW00.USD","LU0912757837.SGD","LU1934455277.USD","LU1162221912.USD","LU2347655156.SGD","LU0661504455.SGD","LU2087621335.USD","ABBV","SG9999001440.SGD","IE0002270589.USD","LU2237443978.SGD","IE00BJJMRZ35.SGD","LU0124676726.USD","LU0234570918.USD","LU0128525929.USD","LU0545039389.USD","LU0198837287.USD","BK4581","LU0985320562.USD","LU1267930490.SGD","LU1496350171.SGD","LU0310800379.SGD","LU0170899867.USD","LU1839511570.USD","LU1585245621.USD","LU0795875086.SGD","LU1989772840.SGD","LU1551013425.SGD","IE00BBT3K403.USD","LU0417517546.SGD","LU2133065610.SGD","IE00BDGV0183.EUR","LU0965509283.SGD","LU0820561909.HKD","LU0211328371.USD","LU0456855351.SGD","BK4534","LU1037948541.HKD","LU1037948897.HKD","SG9999011175.SGD","LU0820561818.USD","LU1061106388.HKD","LU0211327993.USD","LU0708994859.HKD","LU0943347566.SGD","LU1244550577.SGD","LU0795875169.SGD","LU0949170772.SGD","LU1496350502.SGD","SG9999015945.SGD","LU1057294990.SGD","LU2023251221.USD","LU1093756168.USD","IE00BVYPNV92.GBP","LU0882574055.USD","LU1291159041.SGD","LU0965509101.SGD","BK4559","LU0098860793.USD","BK4533","LU1430594728.SGD","LU1003077747.HKD","LU2468319806.SGD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","LU2237443465.HKD","LU1929549753.HKD","LU0203347892.USD","LU1732800096.USD","LU0432979614.USD","BK4566","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"1156023584","title":"艾伯维公司：将通过Trumprx平台为医疗补助计划提供低价药品，并扩大面向患者的可负担直接治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1156023584","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156023584?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:32","pubTimestamp":1768260766,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，将通过其Trumprx平台为医疗补助计划参与者提供低价药品，同时扩大面向患者的可负担直接治疗方案。这一举措旨在提升药品可及性，让更多患者能够以合理价格获得所需治疗。\n通过Trumprx平台，艾伯维将优化药品供应流程，实现从药企到患者的直接服务模式。该战略不仅涵盖价格优惠，还将简化购药流程，为医疗补助计划受益者及自费患者提供更便捷的用药体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU0738911758.USD","LU0310799852.SGD","LU0553294199.USD","LU1732800096.USD","LU0029864427.USD","LU1732799900.SGD","LU0456855351.SGD","LU1934455194.USD","LU1983299246.USD","SG9999015945.SGD","LU1929549753.HKD","LU0158827948.USD","LU2089283258.USD","LU1093756325.SGD","LU1074936037.SGD","LU0203347892.USD","LU0203345920.USD","LU1718418525.SGD","IE0002141913.USD","LU1839511570.USD","LU0211327993.USD","LU0708994859.HKD","SG9999001440.SGD","LU1989771016.USD","IE00BN8TJ469.HKD","LU0234570918.USD","LU0820561818.USD","LU1291159041.SGD","LU1934455277.USD","LU2089984988.USD","LU2237443895.HKD","LU1585245621.USD","IE0009355771.USD","LU0122379950.USD","LU0861579265.USD","LU2129689514.USD","LU1551013425.SGD","IE00B42XCP33.USD","SG9999015986.USD","LU1244550494.USD","LU1037948541.HKD","LU0289739699.SGD","LU1934455863.HKD","ABBV","LU1023059063.AUD","LU0098860793.USD","BK4550","LU1093756168.USD","IE00BSNM7G36.USD","LU2237443382.USD","IE0004445239.USD","SG9999011175.SGD","IE00B3PB1722.GBP","LU0124676726.USD","LU0661504455.SGD","LU1496350502.SGD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU2237443622.USD","LU2468319806.SGD","LU1496350171.SGD","LU0310800379.SGD","LU0128525929.USD","BK4534","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1244550577.SGD","LU0432979614.USD","LU2237443465.HKD","LU0256863811.USD","LU2129689605.HKD","IE00BVYPNW00.USD","LU0211328371.USD","LU0058720904.USD","LU2089284900.SGD","LU0965509010.AUD","LU0320765646.SGD","LU2129689431.USD","LU0198837287.USD","LU1061106388.HKD","SG9999015952.SGD","BK4588","LU2133065610.SGD","IE00BVYPNV92.GBP","BK4559","IE00BGHQF631.EUR","IE00BLSP4239.USD","LU1989772840.SGD","IE0002270589.USD","IE00B19Z3581.USD","IE00BJT1NW94.SGD","LU0256863902.USD","LU1244550221.USD","LU2023251221.USD","LU0545039389.USD","LU2087621335.USD","LU0689472784.USD","BK4139","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU1267930573.SGD","BK4566","LU0912757837.SGD","LU0795875169.SGD","LU2112291526.USD","LU0965509101.SGD","IE00BBT3K403.USD","LU2237443978.SGD","LU1989772923.USD","LU0965508806.USD","BK4585","SG9999015978.USD","LU1551013342.USD","LU1430594728.SGD","LU0234572021.USD","LU0795875086.SGD","LU1003077747.HKD","LU0949170772.SGD","BK4533","LU0417517546.SGD","BK4581","LU0965509283.SGD","LU0689626769.HKD","LU0943347566.SGD","LU1267930490.SGD","LU0985320562.USD","LU1057294990.SGD","LU0170899867.USD","LU2237443549.SGD","LU0820561909.HKD","LU0882574055.USD","LU1162221912.USD","SG9999003800.SGD","LU0114720955.EUR","IE00BDGV0183.EUR","LU2347655156.SGD"],"gpt_icon":0},{"id":"1129514473","title":"Solid Biosciences旗下SGT-212双路径基因疗法获FDA孤儿药认定 用于治疗弗里德赖希共济失调","url":"https://stock-news.laohu8.com/highlight/detail?id=1129514473","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129514473?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:16","pubTimestamp":1768252619,"startTime":"0","endTime":"0","summary":"Solid Biosciences宣布，其研发的SGT-212双路径基因疗法已获得美国食品药品监督管理局授予的孤儿药认定，适应症为弗里德赖希共济失调。获得该认定后，Solid Biosciences将在药物开发和商业化过程中享受一系列政策支持，包括临床试验费用税收抵免、豁免部分申请费用以及上市后七年的市场独占权。弗里德赖希共济失调是一种遗传性神经系统疾病，目前尚无有效治疗方法。SGT-212通过双路径给药机制，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"1157703345","title":"Solid Biosciences：完成1B期Falcon试验首名受试者给药，初步数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1157703345","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157703345?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:16","pubTimestamp":1768252580,"startTime":"0","endTime":"0","summary":"Solid Biosciences（SLDB）宣布，其1B期Falcon临床试验已完成对首位参与者的给药程序。该试验旨在评估其在研疗法的安全性与有效性。\n公司预计将于2026年下半年获得并公布这项研究的初步数据。此次进展标志着该药物临床开发计划中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"1144961515","title":"Crinetics Pharmaceuticals公布2026年1月根据纳斯达克上市规则5635(C)(4)授予的诱导性股权奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1144961515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144961515?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:06","pubTimestamp":1768251976,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.（以下简称\"公司\"）近日披露，已依据纳斯达克市场上市规则第5635(C)(4)条，于2026年1月向新入职员工授予诱导性股权奖励。此类奖励作为行业常规人才引进措施，旨在吸引高端科研人才加入研发团队。根据相关规定，该次授予计划无需经过股东大会批准，符合新兴生物科技企业通过股权激励构建核心竞争力的普遍实践。公司强调，此次股权分配严格遵循合规流程，展现了其持续强化代谢疾病创新疗法研发实力的战略决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"gpt_icon":0},{"id":"2603755255","title":"Benitec Biopharma Inc.盘中异动 下午盘大幅上涨5.57%报12.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603755255","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603755255?lang=zh_cn&edition=full","pubTime":"2026-01-13 04:07","pubTimestamp":1768248451,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日04时07分，Benitec Biopharma Inc.股票出现波动，股价快速上涨5.57%。截至发稿，该股报12.50美元/股，成交量11.4163万股，换手率0.34%，振幅8.28%。Benitec Biopharma Inc.股票所在的生物技术行业中，整体跌幅为1.06%。Benitec Biopharma Inc.公司简介：Benitec Biopharma Inc 是一家临床阶段的生物技术公司，专注于新型基因药物的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113040731953c7520&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113040731953c7520&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BNTC"],"gpt_icon":0},{"id":"1189517059","title":"吉利德科学高管披露：已向FDA提交Anito-Cel申请，预计本季度获受理函，目标2026年下半年上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1189517059","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189517059?lang=zh_cn&edition=full","pubTime":"2026-01-13 03:31","pubTimestamp":1768246278,"startTime":"0","endTime":"0","summary":"吉利德科学高管近日透露，公司已正式向美国食品药品监督管理局（FDA）提交嵌合抗原受体T细胞疗法Anito-Cel的上市申请。目前正等待监管机构发出受理确认函，预计将于本季度内收到相关通知。若审批进展顺利，该疗法计划于2026年下半年正式推向市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0320765992.SGD","LU1585245621.USD","IE00BKVL7J92.USD","BK4583","LU1066051498.USD","LU0823416689.USD","LU0882574055.USD","SG9999015986.USD","GILD","SG9999015952.SGD","IE00B19Z3581.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU1778281490.HKD","BK4588","LU1066053197.SGD","LU1674673691.USD","BK4139","LU2324357040.USD","LU2087621335.USD","BK4532","LU1430594728.SGD","IE0002270589.USD","LU2089984988.USD","LU1839511570.USD","IE00B19Z3B42.SGD","BK4566","SG9999015945.SGD","LU1571399168.USD","LU0058720904.USD","IE00B3T34201.USD","BK4585","LU0114720955.EUR","LU2468319806.SGD","LU0109394709.USD","BK4578","IE00B7SZLL34.SGD","LU0234570918.USD","LU0289739699.SGD","SG9999015978.USD","BK4550","LU1674673428.USD","BK4568"],"gpt_icon":0},{"id":"1166649682","title":"吉利德高管透露：Lenacapavir去年底首次在撒哈拉以南非洲国家完成交付 与美国上市同年实现","url":"https://stock-news.laohu8.com/highlight/detail?id=1166649682","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166649682?lang=zh_cn&edition=full","pubTime":"2026-01-13 03:28","pubTimestamp":1768246101,"startTime":"0","endTime":"0","summary":"吉利德科学公司高管近日披露，其创新HIV治疗药物Lenacapavir于去年年底首次在撒哈拉以南非洲地区完成交付。这一里程碑事件的发生时间，恰逢该药物同期在美国市场正式推出之年。此次突破性进展标志着抗艾滋病药物可及性的重要跨越，凸显了创新医疗方案向全球高危区域同步推进的战略意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","BK4550","LU2468319806.SGD","BK4583","BK4139","LU1066053197.SGD","BK4578","SG9999015986.USD","LU2324357040.USD","IE00BKVL7J92.USD","BK4532","SG9999015978.USD","LU0058720904.USD","IE00B3T34201.USD","LU1571399168.USD","LU0823416689.USD","LU0320765992.SGD","LU0234570918.USD","LU0109394709.USD","IE00BSNM7G36.USD","SG9999015945.SGD","BK4568","LU0114720955.EUR","IE00B19Z3B42.SGD","LU0882574055.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU1674673428.USD","LU1430594728.SGD","BK4588","LU1778281490.HKD","LU1066051498.USD","BK4585","BK4566","IE0002270589.USD","LU0289739699.SGD","LU1839511570.USD","LU2087621335.USD","GILD","LU1674673691.USD","IE00B7SZLL34.SGD","LU2089984988.USD","LU0889565916.HKD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2603578019","title":"诺瓦瓦克斯医药盘中异动 股价大涨5.02%报7.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603578019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603578019?lang=zh_cn&edition=full","pubTime":"2026-01-13 02:54","pubTimestamp":1768244079,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日02时54分，诺瓦瓦克斯医药股票出现波动，股价急速拉升5.02%。截至发稿，该股报7.63美元/股，成交量201.506万股，换手率1.24%，振幅6.46%。机构评级方面，在所有10家参与评级的机构中，50%的券商给予买入建议，20%的券商给予持有建议，30%的券商给予卖出建议。诺瓦瓦克斯医药股票所在的生物技术行业中，整体跌幅为1.64%。公司认为其疫苗技术有潜力广泛应用于多种人类传染病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113025439953c74c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113025439953c74c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BK4568","BK4585","NVAX","BK4588","BK4139"],"gpt_icon":0},{"id":"1171793741","title":"居里公布创新放射性药物Utreat针对高级别胶质瘤一期试验的积极初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1171793741","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171793741?lang=zh_cn&edition=full","pubTime":"2026-01-13 02:10","pubTimestamp":1768241443,"startTime":"0","endTime":"0","summary":"居里公司近日发布了其创新放射性药物Utreat在一期临床试验中的初步数据，该试验针对高级别胶质瘤患者。初步结果显示，Utreat在试验中表现出积极的疗效和安全性，为后续研究奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRIS"],"gpt_icon":0},{"id":"2603521809","title":"Whitehawk Therapeutics, Inc.盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603521809","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603521809?lang=zh_cn&edition=full","pubTime":"2026-01-13 01:31","pubTimestamp":1768239115,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日01时31分，Whitehawk Therapeutics, Inc.股票出现异动，股价快速跳水5.30%。Whitehawk Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.67%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Cellectar Biosciences, Inc.、Beam Therapeutics Inc.涨幅较大，Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃，换手率分别为642.52%、132.36%、100.72%，振幅较大的相关个股有Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Mindwalk Holdings Corp.，振幅分别为32.48%、31.29%、31.25%。Whitehawk Therapeutics, Inc.公司简介：Whitehawk Therapeutics Inc 是一种临床前阶段的肿瘤治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113013155a7127730&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113013155a7127730&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","BK4139","WHWK","LENZ"],"gpt_icon":0},{"id":"1145314898","title":"渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1145314898","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145314898?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:11","pubTimestamp":1768234293,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准渤健公司针对脊髓性肌萎缩症的Spiranza®（Nusinersen）高剂量治疗方案。这一监管里程碑标志着该疗法在欧盟市场获得重要拓展，为患者群体提供更具灵活性的用药选择。\n此次获批的高剂量方案将进一步提升药物在临床实践中的应用价值，凸显渤健公司在神经科学治疗领域持续创新的战略布局。监管机构的认可也为该疗法在更广泛患者群体中的使用铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0234570918.USD","BIIB","IE00B19Z9Z06.USD","BK4585","IE00B19Z9P08.USD","IE00B894F039.SGD","IONS","LU0109394709.USD","LU0320765992.SGD","BK4588","LU0889565916.HKD","BK4532","BK4139"],"gpt_icon":0},{"id":"2603578527","title":"Prothena Corporation Plc盘中异动 早盘急速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603578527","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603578527?lang=zh_cn&edition=full","pubTime":"2026-01-12 23:31","pubTimestamp":1768231908,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日23时31分，Prothena Corporation Plc股票出现波动，股价大幅下挫5.00%。截至发稿，该股报8.73美元/股，成交量8.1218万股，换手率0.15%，振幅4.46%。Prothena Corporation Plc股票所在的生物技术行业中，整体跌幅为1.42%。Prothena Corporation Plc公司简介：Prothena Corp PLC是一家临床生物技术公司，专注于蛋白质失调和具有改变破坏性神经退行性疾病以及罕见和周围淀粉样蛋白疾病进程潜力的研究性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112233149953c70b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112233149953c70b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4572","AL","IE00B19Z6F94.USD","PRTA","IE0034390439.USD","LU1169590202.USD","BK4104","LU1169589451.USD","BK4139"],"gpt_icon":0},{"id":"2603242345","title":"Neurogene Inc.盘中异动 大幅下跌5.41%报16.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603242345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603242345?lang=zh_cn&edition=full","pubTime":"2026-01-12 23:22","pubTimestamp":1768231341,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日23时22分，Neurogene Inc.股票出现波动，股价快速跳水5.41%。截至发稿，该股报16.95美元/股，成交量1.9541万股，换手率0.13%，振幅5.30%。Neurogene Inc.股票所在的生物技术行业中，整体跌幅为1.25%。其相关个股中，Forte Biosciences, Inc.、Beam Therapeutics Inc.、Cellectar Biosciences, Inc.涨幅较大，Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃，换手率分别为583.73%、121.98%、70.69%，振幅较大的相关个股有Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Cdt Equity Inc C/Wts 22/09/2028，振幅分别为32.48%、31.29%、29.73%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011223222197a17983&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011223222197a17983&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2603572199","title":"Passage Bio, Inc.盘中异动 早盘股价大跌6.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603572199","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603572199?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:54","pubTimestamp":1768229664,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时54分，Passage Bio, Inc.股票出现波动，股价快速下跌6.30%。截至发稿，该股报18.60美元/股，成交量7315股，换手率0.23%，振幅4.79%。Passage Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，Cdt Equity Inc C/Wts 22/09/2028、Beam Therapeutics Inc.、Day One Biopharmaceuticals, Inc.涨幅较大，Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃，换手率分别为554.06%、118.22%、59.28%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Pyxis Oncology, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为31.29%、26.42%、25.56%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112225425a4bb1fec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112225425a4bb1fec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}